What's all this talk about this abbvie purchase of BI 655066 for Plaque Psoriasis. Best in class blah blah blah..
BI 655066 is for Mod/severe Plaque Psoriasis. Which accounts for 20% of all plaque psoriasis...as is Stelara and Otezla......NOTHING for MILD psoriasis!!
PRURISOL on the other hand treats MILD to Moderate PS which accounts for 80% of all Plaque Psoriasis.
MILD Psoriasis is treated with creams lotions etc....which offer little relief.
Like Leo said...."Based on compelling pre-clinical data, Cellceutix purposely set the bar high for the Phase 2 trial by targeting mild to moderate plaque psoriasis with an oral drug. By doing this, the Company is assessing Prurisol potentially for two different and very large markets in the psoriasis space. First, there are currently limited oral medications for mild to moderate chronic plaque psoriasis. Second, there is a need for new non-biologic oral treatments for moderate to severe chronic plaque psoriasis.
BI 655066 is for Mod/severe Plaque Psoriasis. Which accounts for 20% of all plaque psoriasis...as is Stelara and Otezla......NOTHING for MILD psoriasis!!
PRURISOL on the other hand treats MILD to Moderate PS which accounts for 80% of all Plaque Psoriasis.
MILD Psoriasis is treated with creams lotions etc....which offer little relief.
Like Leo said...."Based on compelling pre-clinical data, Cellceutix purposely set the bar high for the Phase 2 trial by targeting mild to moderate plaque psoriasis with an oral drug. By doing this, the Company is assessing Prurisol potentially for two different and very large markets in the psoriasis space. First, there are currently limited oral medications for mild to moderate chronic plaque psoriasis. Second, there is a need for new non-biologic oral treatments for moderate to severe chronic plaque psoriasis.
